Amylyx Pharmaceuticals AMLX Balance Sheet (2021-2026)

NASDAQ AMLX
$33.27 -0.61 (-1.80%)
As of: Sep 9, 2026 · 11:19 AM EDT
Reported Financials

Amylyx Pharmaceuticals Quarterly Balance Sheet

Periods 22 quarters
Latest Jun 2026

Amylyx Pharmaceuticals reported total assets of $264.56M and total liabilities of $25.40M for the quarter ended Jun 2026, up 36.0% year over year. This balance sheet covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Accumulated Depreciation
0.05M0.54M1.63M1.36M1.55M
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
50.19M110.40M67.44M107.73M62.53M114.56M247.76M135.26M170.20M170.55M75.00M71.84M77.39M59.76M58.09M225.18M226.65M229.14M49.33M
Receivables - NetNet Receivables
0.14M15.31M17.55M33.47M29.35M40.05M20.35M4.09M1.73M0.45M0.30M0.10M0.13M0.09M
Receivables - OtherOther Receivables
0.50M0.30M0.80M0.10M0.50M0.30M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.50M
Receivables
0.14M15.81M17.86M34.27M29.45M40.55M20.65M4.19M1.83M0.55M0.40M0.20M0.23M0.19M
Raw Materials
0.41M7.15M
Work In Process
0.04M1.68M
Finished Goods
0.11M0.94M
Inventory
0.56M9.77M13.07M24.86M32.37M38.32M
Prepaid Assets
5.39M10.28M9.46M8.34M10.11M12.75M11.79M17.34M14.93M16.89M12.82M9.14M12.48M11.78M5.96M9.26M6.69M5.26M5.58M
Current Assets
104.95M265.49M216.14M172.20M382.13M389.05M427.39M434.11M464.67M410.53M326.72M245.26M189.43M216.14M186.89M353.38M323.67M285.02M256.34M
Non-Current Assets
Property, Plant & Equipment (Net)
0.47M1.29M1.86M2.12M2.61M2.56M2.64M2.76M2.69M2.46M1.47M1.25M0.96M0.82M0.45M0.40M0.31M0.21M0.20M
Long-Term Investments
10.07M17.73M24.33M44.96M
Other Non-Current Assets
3.44M0.46M0.46M0.72M0.72M0.72M0.72M0.72M0.72M0.72M0.72M1.44M1.45M1.45M1.45M2.50M2.50M2.50M2.50M
Non-Current Assets
0.66M8.95M9.10M9.24M9.32M18.91M26.19M32.47M52.79M6.92M5.44M5.45M4.20M3.53M7.71M9.36M8.97M8.58M8.23M
Assets
105.61M274.44M225.24M181.44M391.45M407.96M453.59M466.58M517.45M417.46M332.16M250.71M193.63M219.68M194.60M362.74M332.64M293.60M264.56M
Liabilities
Current Liabilities
Accounts Payables
4.37M10.04M8.12M7.05M6.26M10.77M24.70M6.37M22.06M21.45M4.96M1.49M2.94M4.81M3.29M5.34M3.52M3.53M5.53M
Payables
4.37M10.04M8.12M7.05M6.26M10.77M24.70M6.37M22.06M21.45M4.96M1.49M2.94M4.81M3.29M5.34M3.52M3.53M5.53M
Accumulated Expenses
13.02M16.26M17.26M23.61M38.31M38.75M37.24M37.05M57.72M67.87M62.76M50.46M23.95M12.07M17.46M19.47M17.91M11.28M14.61M
Other Accumulated Expenses
0.26M0.44M0.54M0.36M1.00M
Current Leases
1.41M1.79M1.99M2.04M2.09M2.15M2.20M2.26M2.31M2.37M1.97M1.52M1.05M0.67M0.98M1.26M1.16M1.01M
Total Current Liabilities
17.40M27.71M27.16M32.65M46.61M51.62M64.08M45.62M82.04M91.64M70.08M53.91M28.41M17.93M21.42M25.79M22.69M15.97M21.15M
Non-Current Liabilities
Non-Current Deffered Revenue
0.04M
Preferred Stock Liabilities
134.79M239.35M
Operating Leases
5.79M5.29M4.77M4.24M3.69M3.14M2.57M1.98M1.38M0.77M5.10M0.46M0.33M5.30M4.95M4.70M4.48M4.25M
Total Liabilities
124.07M17.43M33.49M32.45M37.41M50.85M55.31M67.22M48.18M84.02M93.02M70.85M54.51M28.87M18.26M26.72M30.75M27.39M20.44M25.40M
Shareholder's Equity
Common Equity
-124.07M-151.17M240.95M192.79M144.03M340.61M352.65M386.37M418.40M433.43M324.44M261.31M196.20M164.76M201.42M167.88M332.00M305.26M273.16M239.17M
Liabilities and Shareholders Equity
105.61M274.44M225.24M181.44M391.45M407.96M453.59M466.58M517.45M417.46M332.16M250.71M193.63M219.68M194.60M362.74M332.64M293.60M264.56M
Retained Earnings
-155.84M-203.70M-257.80M-311.52M-354.22M-352.65M-330.57M-309.68M-304.95M-423.74M-496.44M-569.15M-606.69M-642.60M-684.04M-718.43M-751.43M-792.71M-836.13M
Treasury Shares
14.50M37.11M